Miao Ruixue, Wang Zhiling, Guo Qin, Wen Yang, Liao Qiong, Zhu Yu, Shu Min, Wan Chaomin
From the *Department of Pediatrics, West China Second Hospital, Sichuan University, Chengdu, People's Republic of China; and †Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, People's Republic of China.
Pediatr Infect Dis J. 2017 Jan;36(1):9-12. doi: 10.1097/INF.0000000000001343.
Visceral leishmaniasis (VL) is a life-threatening parasitic infection transmitted by phlebotomine sandflies. We undertook this study to analyze the clinical features of pediatric VL in a population of Chinese children.
A retrospective study was performed with pediatric patients (≤14 years) diagnosed with VL based on bone marrow biopsy, serology and diagnosis based on clinical manifestation and the improvement after the experimental drug when negative bone marrow and serology results were shown in West China Second Hospital, between January 2001 and December 2015.
A total of 43 patients were determined as having a VL infection (ranging from 4 months to 12 years with a slight male preponderance). Sixty-seven percent were less than 5 years of age and 74% of patients resided in endemic regions. The average time to diagnosis from the onset of symptoms was 37.5 days (ranging from 5 days to 6 months). The main clinical manifestations were fever (98%), splenomegaly (98%), hepatomegaly (74%), pancytopenia (72%), pallor (33%), cough (33%) and lymphadenopathy (33%). Hepatic dysfunction was also found in 24 patients (68%). All patients were treated with meglumine antimonite; only 1 child was treated with liposomal amphotericin B after resistance to meglumine antimonite was discovered. Patients were clinically cured except for 1 patient, who died from hemorrhagic shock because of refusal of standard treatment.
Although there were no specific clinical manifestations of pediatric VL, a characterization of the overall symptoms may lead to an improved awareness of VL by clinicians and prompt early diagnosis and treatments. Presently, pentavalent antimony remains the first-line drug and there is low resistance in China.
内脏利什曼病(VL)是一种由白蛉传播的危及生命的寄生虫感染。我们开展这项研究以分析中国儿童群体中儿童VL的临床特征。
对2001年1月至2015年12月期间在华西第二医院诊断为VL的儿科患者(≤14岁)进行回顾性研究,这些患者基于骨髓活检、血清学诊断,以及在骨髓和血清学结果为阴性时根据临床表现及试验性药物治疗后的改善情况进行诊断。
共确定43例患者感染VL(年龄范围为4个月至12岁,男性略占优势)。67%的患者年龄小于5岁,74%的患者居住在流行地区。从症状出现到诊断的平均时间为37.5天(范围为5天至6个月)。主要临床表现为发热(98%)、脾肿大(98%)、肝肿大(74%)、全血细胞减少(72%)、面色苍白(33%)、咳嗽(33%)和淋巴结病(33%)。24例患者(68%)还存在肝功能障碍。所有患者均接受葡甲胺锑治疗;仅1例患儿在发现对葡甲胺锑耐药后接受了脂质体两性霉素B治疗。除1例因拒绝标准治疗死于失血性休克的患者外,其余患者均临床治愈。
尽管儿童VL没有特异性临床表现,但对总体症状的特征描述可能会提高临床医生对VL的认识,并促使早期诊断和治疗。目前,五价锑仍然是一线药物,在中国耐药率较低。